JP2015017135A - 制癌剤副作用抑制剤ならびに予後改善剤 - Google Patents
制癌剤副作用抑制剤ならびに予後改善剤 Download PDFInfo
- Publication number
- JP2015017135A JP2015017135A JP2014218444A JP2014218444A JP2015017135A JP 2015017135 A JP2015017135 A JP 2015017135A JP 2014218444 A JP2014218444 A JP 2014218444A JP 2014218444 A JP2014218444 A JP 2014218444A JP 2015017135 A JP2015017135 A JP 2015017135A
- Authority
- JP
- Japan
- Prior art keywords
- fucoidan
- mozuku
- agent
- containing material
- colorectal cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000694 effects Effects 0.000 title claims abstract description 46
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 31
- 239000003112 inhibitor Substances 0.000 title claims abstract description 13
- 238000004393 prognosis Methods 0.000 title claims abstract description 11
- 239000002246 antineoplastic agent Substances 0.000 title description 15
- 229920000855 Fucoidan Polymers 0.000 claims abstract description 101
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 40
- 239000000463 material Substances 0.000 claims abstract description 31
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims abstract description 30
- 229960002949 fluorouracil Drugs 0.000 claims abstract description 30
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 34
- 238000001050 pharmacotherapy Methods 0.000 claims description 30
- 210000002249 digestive system Anatomy 0.000 claims description 5
- 238000002651 drug therapy Methods 0.000 abstract description 19
- 208000029742 colonic neoplasm Diseases 0.000 abstract description 5
- YXTKHLHCVFUPPT-YYFJYKOTSA-N (2s)-2-[[4-[(2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid;(1r,2r)-1,2-dimethanidylcyclohexane;5-fluoro-1h-pyrimidine-2,4-dione;oxalic acid;platinum(2+) Chemical compound [Pt+2].OC(=O)C(O)=O.[CH2-][C@@H]1CCCC[C@H]1[CH2-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 YXTKHLHCVFUPPT-YYFJYKOTSA-N 0.000 description 14
- 206010016256 fatigue Diseases 0.000 description 13
- JYEFSHLLTQIXIO-SMNQTINBSA-N folfiri regimen Chemical compound FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 JYEFSHLLTQIXIO-SMNQTINBSA-N 0.000 description 13
- 206010047700 Vomiting Diseases 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- 229940041181 antineoplastic drug Drugs 0.000 description 8
- 241001474374 Blennius Species 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 206010028813 Nausea Diseases 0.000 description 5
- 239000003560 cancer drug Substances 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 230000008693 nausea Effects 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 230000008673 vomiting Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000004596 appetite loss Effects 0.000 description 3
- 229940120638 avastin Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 208000019017 loss of appetite Diseases 0.000 description 3
- 235000021266 loss of appetite Nutrition 0.000 description 3
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 3
- 229960001756 oxaliplatin Drugs 0.000 description 3
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000199919 Phaeophyceae Species 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 241001261506 Undaria pinnatifida Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 2
- 235000008191 folinic acid Nutrition 0.000 description 2
- 239000011672 folinic acid Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
- 229960001691 leucovorin Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- UEJQGOKMPMUMTO-UHFFFAOYSA-N C(C#C)OC1=NC=C(C(=N1)OCC#C)F Chemical compound C(C#C)OC1=NC=C(C(=N1)OCC#C)F UEJQGOKMPMUMTO-UHFFFAOYSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 208000006478 Cecal Neoplasms Diseases 0.000 description 1
- 241000980780 Cladosiphon okamuranus Species 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- -1 FOLFOX or FOLFIRI Chemical compound 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 235000002492 Rungia klossii Nutrition 0.000 description 1
- 244000117054 Rungia klossii Species 0.000 description 1
- 208000009125 Sigmoid Neoplasms Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 201000010838 ascending colon cancer Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 201000003959 cecum carcinoma Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 208000024389 cytopenia Diseases 0.000 description 1
- 201000003823 descending colon cancer Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000009950 gastric cancer growth Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000009101 premedication Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 1
- 201000003825 sigmoid colon cancer Diseases 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 201000010986 transverse colon cancer Diseases 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
【解決手段】フコイダンまたはフコイダン含有素材を含む、5−フルオロウラシルを用いる大腸癌の薬物療法の副作用抑制剤であって、副作用が中等症(NCI−CTC基準の2点)以上のものである副作用抑制剤、ならびにフコイダンまたはフコイダン含有素材を含む、5−フルオロウラシルを用いる大腸癌の薬物療法の予後改善剤。
【選択図】なし
Description
(1)フコイダンまたはフコイダン含有素材を含む、5−フルオロウラシルを用いる大腸癌の薬物療法の副作用抑制剤;
(2)該薬物療法がFOLFOXおよび/またはFOLFIRIである(1)
記載の副作用抑制剤;
(3)該副作用が消化器系副作用および/または疲労感である(1)または(2)記載の副作用抑制剤;
(4)フコイダンがもずく由来のものであるか、フコイダン含有素材がもずくである、(1)〜(3)のいずれかに記載の副作用抑制剤;
(5)フコイダンまたはフコイダン含有素材を大腸癌患者に投与することを特徴とする、5−フルオロウラシルを用いる大腸癌の薬物療法の副作用抑制方法;
(6)該薬物療法がFOLFOXおよび/またはFOLFIRIである(5)記載の方法;
(7)該副作用が消化器系副作用および/または疲労感である(5)または(6)記載の方法;
(8)フコイダンがもずく由来のものであるか、フコイダン含有素材がもずくである、(5)〜(7)のいずれかに記載の方法;
(9)5−フルオロウラシルを用いる大腸癌の薬物療法の副作用抑制剤の製造のための、フコイダンまたはフコイダン含有素材の使用;
(10)該薬物療法がFOLFOXおよび/またはFOLFIRIである(9)記載の使用;
(11)該副作用が消化器系副作用および/または疲労感である(9)または(10)記載の使用;
(12)該副作用抑制剤によって成人1日あたり約3〜約5g(乾燥重量)のフコイダンが投与される、(9)〜(11)のいずれかに記載の使用;
(13)フコイダンの分子量が約30万である、(9)〜(12)のいずれかに記載の使用;
(14)フコイダンがもずく由来のものであるか、フコイダン含有素材がもずくである、(9)〜(13)のいずれか1項記載の使用;
(15)該薬物療法がFOLFOXおよび/またはFOLFIRIであり、該副作用が疲労感、食欲の低下、悪心および嘔吐からなる群より選択される1つ以上のものであり、該副作用抑制剤によって成人1日あたり約0.5〜約5g(乾燥重量)のフコイダンが投与され、フコイダンの分子量が約30万であり、フコイダンがもずく由来のものであるか、フコイダン含有素材がもずくである、請求項9〜14のいずれか1項記載の使用。
さらに本発明は以下のものを提供する。
(16)フコイダンまたはフコイダン含有素材を含む、5−フルオロウラシルを用いる大腸癌の薬物療法の予後改善剤;
(17)フコイダンまたはフコイダン含有素材を大腸癌患者に投与することを特徴とする、5−フルオロウラシルを用いる大腸癌の薬物療法の予後改善方法;
(18)5−フルオロウラシルを用いる大腸癌の薬物療法の予後改善剤の製造のための、フコイダンまたはフコイダン含有素材の使用。
1)プレメディケーションとして5−HT3拮抗薬ならびにステロイドを投与する。
2)L−OHP(オキサリプラチン)85mg/m2を250mLの5%ブドウ糖液に溶解する。
3)1−LV(レボホリナート)200mg/m2を250mLの5%ブドウ糖液に溶解する。
4)2)と3)を別々のバッグに入れてYラインを使用し、同時に2時間かけて静注する。
5)5−FU 400mg/m2を15分以内で急速静注する。
6)5−FU 2400mg/m2を46時間かけて持続静注する。
7)治療期間2日目より3日間経口ステロイド剤を投与する。
1.食欲の低下、2.悪心、嘔吐、3.下痢、4.口内炎、5.神経症状、6.疲労感、7.血球減少
について、NCI−CTC基準に照らして評点をつけた。評価は投与期間中、3ヶ月ごとに行った。上記試験において解析可能であった患者数は、フコイダン投与群では9名、フコイダン非投与群では8名であった。
Claims (5)
- フコイダンまたはフコイダン含有素材を含む、5−フルオロウラシルを用いる大腸癌の薬物療法の副作用抑制剤であって、副作用が中等症(NCI−CTC基準の2点)以上のものである副作用抑制剤。
- フコイダンがもずく由来のものであるか、フコイダン含有素材がもずくであり、フコイダンの分子量が30万である、請求項1記載の剤。
- 該副作用が消化器系副作用および/または疲労感である請求項1または2記載の剤。
- フコイダンまたはフコイダン含有素材を含む、5−フルオロウラシルを用いる大腸癌の薬物療法の予後改善剤。
- フコイダンがもずく由来のものであるか、フコイダン含有素材がもずくであり、フコイダンの分子量が30万である、請求項4記載の剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014218444A JP5875660B2 (ja) | 2009-09-28 | 2014-10-27 | 制癌剤副作用抑制剤ならびに予後改善剤 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009222553 | 2009-09-28 | ||
JP2009222553 | 2009-09-28 | ||
JP2014218444A JP5875660B2 (ja) | 2009-09-28 | 2014-10-27 | 制癌剤副作用抑制剤ならびに予後改善剤 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011532918A Division JPWO2011036904A1 (ja) | 2009-09-28 | 2010-02-22 | 制癌剤副作用抑制剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015017135A true JP2015017135A (ja) | 2015-01-29 |
JP5875660B2 JP5875660B2 (ja) | 2016-03-02 |
Family
ID=43795671
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011532918A Pending JPWO2011036904A1 (ja) | 2009-09-28 | 2010-02-22 | 制癌剤副作用抑制剤 |
JP2014218444A Active JP5875660B2 (ja) | 2009-09-28 | 2014-10-27 | 制癌剤副作用抑制剤ならびに予後改善剤 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011532918A Pending JPWO2011036904A1 (ja) | 2009-09-28 | 2010-02-22 | 制癌剤副作用抑制剤 |
Country Status (4)
Country | Link |
---|---|
US (1) | US8974796B2 (ja) |
EP (1) | EP2484367B1 (ja) |
JP (2) | JPWO2011036904A1 (ja) |
WO (1) | WO2011036904A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015051970A (ja) * | 2013-09-06 | 2015-03-19 | マイクロバイオ カンパニー, リミテッド | 化学療法を受けているがん患者向けのアジュバントを製造するための組成物 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001031575A (ja) * | 1999-07-16 | 2001-02-06 | Fujibio Co Ltd | キチン・キトサンによる5−フルオロウラシルの副作用防止方法及びそのための配合剤 |
JP2004075595A (ja) * | 2002-08-14 | 2004-03-11 | Kaisanbutsuno Kimuraya:Kk | 薬剤の副作用抑制剤 |
JP2004083558A (ja) * | 2002-04-01 | 2004-03-18 | Sankyo Co Ltd | 抗腫瘍医薬組成物 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007190004A (ja) * | 2006-01-16 | 2007-08-02 | Shinichi Shioda | フコイダン入り健康補助食品 |
JP5311327B2 (ja) * | 2007-03-28 | 2013-10-09 | 国立大学法人鳥取大学 | 硫酸基の脱離を抑えた硫酸化多糖の低分子化物およびその製造方法 |
JP4974940B2 (ja) | 2008-03-17 | 2012-07-11 | Kddi株式会社 | 緊急地震速報配信システム、緊急地震速報配信方法およびプログラム |
-
2010
- 2010-02-22 EP EP10818581.0A patent/EP2484367B1/en active Active
- 2010-02-22 JP JP2011532918A patent/JPWO2011036904A1/ja active Pending
- 2010-02-22 WO PCT/JP2010/052641 patent/WO2011036904A1/ja active Application Filing
- 2010-02-22 US US13/377,887 patent/US8974796B2/en active Active
-
2014
- 2014-10-27 JP JP2014218444A patent/JP5875660B2/ja active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001031575A (ja) * | 1999-07-16 | 2001-02-06 | Fujibio Co Ltd | キチン・キトサンによる5−フルオロウラシルの副作用防止方法及びそのための配合剤 |
JP2004083558A (ja) * | 2002-04-01 | 2004-03-18 | Sankyo Co Ltd | 抗腫瘍医薬組成物 |
JP2004075595A (ja) * | 2002-08-14 | 2004-03-11 | Kaisanbutsuno Kimuraya:Kk | 薬剤の副作用抑制剤 |
Non-Patent Citations (3)
Title |
---|
JPN6010018635; 癌と化学療法 第33巻、第7号, 2006, 第911-914頁 * |
JPN6010018636; 癌と化学療法 第33巻、第7号, 2006, 第904-906頁 * |
JPN6014002468; 石渡 一夫 他: '沖縄モズク由来アセチルフコイダンの癌抑制効果' 静脈経腸栄養 22(4), 2007, 489-495 * |
Also Published As
Publication number | Publication date |
---|---|
WO2011036904A1 (ja) | 2011-03-31 |
EP2484367A1 (en) | 2012-08-08 |
JP5875660B2 (ja) | 2016-03-02 |
JPWO2011036904A1 (ja) | 2013-02-14 |
US8974796B2 (en) | 2015-03-10 |
EP2484367B1 (en) | 2016-07-27 |
US20120087943A1 (en) | 2012-04-12 |
EP2484367A4 (en) | 2013-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050266121A1 (en) | Antioxidative compositions | |
US20190336473A1 (en) | Method for treating cancer with a combination of quercetin and a chemotherapy agent | |
AU2003282829B2 (en) | Antioxidative Compositions | |
CN107205962B (zh) | 手术诱导的恶病质的治疗或预防以及/或者骨髓来源的抑制性细胞和促炎性细胞因子的表达 | |
CA2928675C (en) | Method for the management of cancer and cancer treatment-related comorbidities | |
US7270840B2 (en) | Antioxidative compositions | |
Silvestris et al. | Update on capecitabine alone and in combination regimens in colorectal cancer patients | |
JP5875660B2 (ja) | 制癌剤副作用抑制剤ならびに予後改善剤 | |
US20120065158A1 (en) | Fucoidan having antitumor activity | |
CN113082039A (zh) | 一种用于治疗索拉菲尼耐药肿瘤的组合物及其应用 | |
JP2010106019A (ja) | リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および/または症状軽減剤 | |
JP6895688B2 (ja) | 血液がんの新規治療法及び新規治療剤 | |
US20100048507A1 (en) | Food/beverage and pharmaceutical composition for oral administration for improvement in acidic urine each comprising fucoidan as active ingredient | |
JPWO2014010658A1 (ja) | ヒハツ配合製剤 | |
US20110117070A1 (en) | Compositions and methods for treating headache | |
KR20160141748A (ko) | 항암제 및 부작용 경감제 | |
CN102125569B (zh) | 一种1,6-二磷酸果糖在制备抗癌药物中的应用 | |
KR102265488B1 (ko) | 암 화학 요법시의 부작용 경감제 | |
KR20180106645A (ko) | 6-티오구아닌을 유효성분으로 함유하는 췌장암에 대한 젬시타빈의 항암작용 상승제 조성물 | |
KR101898891B1 (ko) | 진세노사이드 화합물 k를 이용한 세포독성 항암제 부작용 억제용 조성물 | |
TW201934123A (zh) | 預防或治療癌症之包含pi3激酶抑制劑與細胞毒性抗癌物的醫藥組成物 | |
TWI727858B (zh) | 維奈托克(venetoclax)之水溶性高分子衍生物 | |
WO2022014025A1 (ja) | 血液がんの新規治療法及び新規治療剤 | |
Pustelnik et al. | Methotrexate-associated oral mucositis in children with acute lymphoblastic leukemia | |
Chai et al. | The effective combination therapies with irinotecan for colorectal cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20141121 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20141121 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150915 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151112 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160105 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160119 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5875660 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |